Pharmaceutical companies have demonstrated a preference to outsource their peptide synthesis operations to contract service organizations to avail various benefits of their advanced capabilities and access to larger capacities. The growing popularity and rising demand for peptide-based drugs, specifically the GLP-1 peptide drugs, have garnered the attention of stakeholders to further invest in...